Mark Anthony McCamish
CIK 1390798 · President and CEO · last filed 2026-02-12
Mark Anthony McCamish is a President and CEO who has filed 36 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing shows the insider disposed of $1.9M of AVDL on Feb 12, 2026. Across all open-market trades the lifetime net is −$5.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $275.5K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$275.5K
6
36
-$5.36M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Director | 0 | $21.64 | $0 | -$537.1K | 13 | 2026-02-12 |
| RFL | Director | 60,241 | $2.24 | $134.9K | $0 | 3 | 2024-01-08 |
| Vincerx Pharma, Inc. (VINCW) Delisted | Director | — | $1.61 | — | $0 | 1 | 2020-12-28 |
| Forty Seven, Inc. (FTSV) Delisted | President and CEO | 0 | — | — | -$4.82M | 12 | 2020-04-07 |
| FACT | Sr. VP & Chief Medical Officer | 13,200 | $10.65 | $140.6K | $0 | 3 | 2009-04-06 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | SVP & CMO | 14,924 | — | — | $0 | 4 | 2008-12-19 |
Recent Filings
36 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-12 | AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Disp (D) | −89,025 | -$1.87M | EDGAR |
| 2026-02-06 | AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Gift (G) | — | $0 | EDGAR |
| 2025-07-31 | AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Grant (A) | +11,000 | $0 | EDGAR |
| 2024-08-01 | AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Grant (A) | +11,000 | $0 | EDGAR |
| 2024-01-08 | RFL | Grant (A) | +27,655 | $50.1K | EDGAR |
| 2023-12-29 | AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Sell (S) | −75,000 | -$1.09M | EDGAR |
| 2023-08-15 | AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Sell (S) | −28,975 | -$432.6K | EDGAR |
| 2023-08-03 | AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-01-05 | RFL | Grant (A) | +27,174 | $50.0K | EDGAR |
| 2022-08-05 | AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Grant (A) | — | $0 | EDGAR |